91results about How to "Induced proliferation" patented technology

It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and / or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.

The present invention is preparation process of collagen-based surface wound repairing membrane possessing tissue induction function, and features that the collagen-based surface wound repairing membrane modified physically and chemically has introduced gelatin-base slow releasing microsphere containing cell growth factor, pores of 20-200 micron size, pore rate not smaller than 80 %, tensile strength not smaller than 1 MPa, pH 5.0-6.0, and excellent degradation and biocompatibility. It has the functions of absorbing wound diffusate, induce the adhesion, proliferation and differentiation of autocell, induce the growth of blood vessel, release cell growth factor to the wound for long time, speed wound healing and avoid scar. The present invention is used for injury, burns, scalds, skin ulcer, etc.

The present invention provides methods of treating pathologic conditions associated with intestinal ischemia. In the methods, patients at risk for or suffering from intestinal ischemia are treated with a heparin-binding epidermal growth factor product.

Methods and compositions for modulating interleukin-21 (IL-21) / IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21 / IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21 / IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods.

Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and / or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.

Scaffolds made of composite materials and uses thereof in the field of biomedical engineering are disclosed, wherein the composite materials comprise bioactive microparticles that could induce the human bone tissue to regenerate. The scaffolds uses the combination of silicon, calcium, and phosphorus microparticles as bioactive substance that could actively induce the human osteoblasts to proliferate and differentiate, promote the formation and calcification of new bone. Furthermore, the scaffolds employs organic polymer as carrier, takes a three-dimensional structure and external anatomical shape, and exhibits several characteristics compatible with the regeneration of bones and the neogenesis of blood vessels, thereby it could be used safely, economically and effectively for repairing the defect of bone tissue as well as in orthopedic operation of human bone. The present invention also discloses the methods for preparing the scaffolds.

This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods.

The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and / or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.

This invention provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of benign prostate hyperplasia in a male subject, by administering to the subject a selective androgen receptor modulator (SARM) and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein. This invention also provides a method of treating a subject suffering from hair loss, comprising the step of administering to the subject a therapeutically effective amount of a 5-α reductase enzyme type 1 and / or type 2 inhibitor, wherein said inhibitor is a selective androgen receptor modulator (SARM) and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein. This invention also provides a method of inhibiting a 5-α reductase type 1 and / or type 2 enzyme, comprising contacting the enzyme with an effective 5-α reductase inhibitory amount of a selective androgen receptor modulator (SARM) and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, as described herein.

The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.

The invention discloses a low-intensity pulse ultrasound-assisted rotary tubular cell / tissue culture system. The Lipus-assisted rotary tubular cell / tissue culture system comprises a culture main body provided with a rotating shaft, wherein an air chamber is sheathed outside the culture main body, the rotating shaft is arranged at both ends of the air chamber, one end of the culture main body is provided with an Lipus ultrasound instrument, the ultrasound transmitting probe of the Lipus ultrasound instrument is inserted into the culture main body, and the inner wall of the air chamber is provided with an oxygen concentration controlling part. The culture system can realize on-line oxygen supply and liquid supply, thereby being beneficial to the transport of oxygen, carbon dioxide and metabolin in the system and being capable of accurately controlling the oxygen concentration. By using the Lipus ultrasound instrument as an auxiliary means, the invention creates a favorable microenvironment for the proliferation or differentiation of cells or tissues, ultimately simulates the micro-gravity environment for carrying out three-dimensional dynamic culture, and can realize functions of oriented amplification and induced differentiation.

A new protein, named ACA1, has been isolated and purified from the medical fungi Antrodia camphorata using the technique of anion-exchange chromatography. ACA1, a glycoprotein with a molecular mass of 29 kDa, has a pI value of pH 5.3 and contains 118 amino acids in its peptide moiety. In addition, ACA1 contains methionine, half-cystine and histidine residues, which are not existent in FIP-fve and Ling Zhi-8. ACA1 is not able to agglutinate red blood cells from human and mouse. Moreover, ACA1 possesses immunomodulatory activities, which are demonstrated by their stimulatory activity toward RAW 264.7 macrophages and mouse splenocytes. ACA1 can directly enhance the production of tumor necrosis factor-alpha and nitric oxide by RAW 264.7 macrophages, and induce cell proliferation and interferon-gamma secretion by mouse splenocytes.

The present invention relates to compositions and methods of inducing the self-renewal of stem / progenitor supporting cells, including inducing the stem / progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells.

This invention provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of benign prostate hyperplasia in a male subject, by administering to the subject a selective androgen receptor modulator (SARM) and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein. This invention also provides a method of treating a subject suffering from hair loss, comprising the step of administering to the subject a therapeutically effective amount of a 5-α reductase enzyme type 1 and / or type 2 inhibitor, wherein said inhibitor is a selective androgen receptor modulator (SARM) and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein. This invention also provides a method of inhibiting a 5-α reductase type 1 and / or type 2 enzyme, comprising contacting the enzyme with an effective 5-α reductase inhibitory amount of a selective androgen receptor modulator (SARM) and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, as described herein.

The invention relates to the field of gelatin-based biomedical materials, in particular to a preparation method and application of a bionic electronic skin medical stent with a self-repairing function. The method is characterized in that gelatin extracted from an acellular fetal calfskin dermal matrix with good biological safety is used as a raw material; then, conducting polymer poly (3, 4-ethylenedioxythiophene) with good biocompatibility is used; compounding a polystyrene sulfonate (PEDOT: PSS) solution with self-made acidified carbon nanotubes (H-MWCNTs); the hydrogel stent with a multifunctional three-dimensional network space structure is obtained through crosslinking of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), and the hydrogel is good in biocompatibility and high in mechanical strength, has both self-repairing performance and tissue regeneration inducing repairing performance and can be widely applied to skin wound repairing treatment.

The invention provides a carbon fiber composite artificial bone and a preparation method thereof. The section of the artificial bone in a direction perpendicular to the length of the artificial bone is in a U shape, continuous carbon fiber woven fabric composite material layers and carbon fiber non-woven fabric composite material layers are stacked to form the artificial bone, and spaces among thecarbon fibers of the continuous carbon fiber woven fabric composite material layers and the carbon fiber non-woven fabric composite material layers are filled with carbon substrates. The carbon fibercomposite artificial bone has the advantages that the composite material is light in weight, good in biocompatibility, chemical stability and fatigue performance and high in designability, the mechanical property of the composite material is similar to that of a human bone, fake shadows are avoided and the like, hydroxylapatite is stably adhered onto gaps in the surface and the surface, so that biological activity of the composite material is improved, bone growth is facilitated, and bone proliferation is induced.

The invention provides antigenic peptides derived from MAGE-A12 polypeptides and presented by HLA molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.

The invention discloses a three-dimensional bionic self-healing hydrogel fiber scaffold composition and a preparation method and application thereof. The scaffold composition is composed of a biocompatible material, a nano material and a small molecular compound. By using electrostatic spinning, self-crosslinking and mold forming methods, a mixed solution of the biocompatible material, the nano material and the small molecular compound is mixed with an organic solvent in proportion to form a scaffold with biomedical application, particularly a layer-by-layer self-crosslinking three-dimensionalscaffold for muscle regeneration. The biomedical hydrogel fiber scaffold disclosed by the invention can provide cell adhesion sites and signals for inducing cell proliferation and differentiation, has excellent mechanical strength and biodegradability, and has the characteristics of easiness in preparation, low cost, good compatibility and wide application. Rat in-vivo experiments show that: thethree-dimensional bionic hydrogel fiber scaffold can induce differentiation of muscle fibers, reduce oxidative damage to cells and tissues and promote regeneration of muscles and new vessels, and hasgood clinical application conversion value.

The invention provides a method for preparing antibacterial wound dressing with a high chitosan content by means of electrostatic spinning. The method includes preparing mixed solvents for dissolving chitosan; adding the chitosan and polyethylene oxide with an ultrahigh molecular weight into the mixed solvents and heating and stirring the chitosan, the polyethylene oxide and the mixed solvents to obtain mixed solution; carrying out ultrasonic oscillation on the mixed solution and further heating the mixed solution to obtain spinning solution; preparing the antibacterial wound dressing from the obtained spinning solution by the aid of an electrostatic spinning process. The mixed solvents are prepared from nanometer silver solution, dimethyl sulfoxide, acetic acid and surfactants. The method has the advantages that the method is easy and convenient to implement and good in repeatability, the antibacterial wound dressing prepared by the aid of the method is of a nanometer fiber structure, and proliferation, adhesion, spreading and migration of cells can be induced; excellent antibacterial effects can be realized, the antibacterial wound dressing is excellent in biocompatibility, bionic artificial skins are of structures similar to structures of natural skins, accordingly, infection due to diabetes mellitus can be effectively cured, and the antibacterial wound dressing has huge application potential in diabetes mellitus ulcerative wound treatment.

The present invention provides methods of treating pathologic conditions associated with intestinal ischemia. In the methods, patients at risk for or suffering from intestinal ischemia are treated with a heparin-binding epidermal growth factor product.

A peptide-based immunotherapeutic agent effective for every allergy patient is provided. A reagent for typing HLA class II molecules of the patient to be used in selecting a peptide-based immunotherapeutic agent effective for every allergy patient is also provided. The peptide-based immunotherapeutic agent enables the optimal peptide-based immunotherapy for each patient, so that a marked improvement in peptide-immunotherapy can be expected. The peptide-based immunotherapeutic agent is also effective for patients who cannot be treated by peptide-based immunotherapy using major antigen peptide recognized in a particular patient population. Furthermore, the peptide-based immunotherapeutic agent enables simple and easy typing of HLA class II molecules of allergy patients.

The present invention discloses cell lines and recombinant growth factor receptors useful in adoptive cell therapy (ACT), wherein the recombinant growth factor receptor can act as a molecular switch enabling cells expressing the rGFR protein to be expanded in-vitro or in- vivo. Thus the invention provides a T or NK cell, comprising a recombinant growth factor receptor (rGFR) comprising: (i) an extracellular (EC) domain; (ii) a thrombopoietin receptor transmembrane (TM) domain; and (iii) a growth factor receptor intracellular (IC) domain.

Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and / or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.

The invention relates to in-vitro culture of immune cells and in particular relates to in-vitro induction culture of CIK cells. The preparation method disclosed by the invention comprises the following steps: coating a cell culture bottle by fibronectin and a CD3 monoclonal antibody; preparing autologous plasma; acquiring peripheral blood mononuclear cells PBMC; inducing the PBMC by IL-2, IFN-gamma and the autologous plasma; and performing multiplication culture. The CIK cells prepared by the preparation method disclosed by the invention are great in quantity of CIK cells, high in cell viability, high in ratio of CD3+CD56+effector cells and high in cytolytic activity, can meet clinical requirements and have high anti-tumor abilities.

The invention provides a cellular immunotherapy therapy product comprising CAR T cells that are enriched in CD8+ cells. Also provided are methods for making and using the product.